Artemis Therapeutics
Human Ingenuity — Amplified by AI

Science

Augmenting Drug Discovery at
an Unprecedented Scale

Sample text/outline: The combination of our long-standing scientific expertise in the field of prostate cancer and the development, application, and integration of the latest technologies gives us a tremendous competitive edge. We design and screen molecules at an extraordinary pace. As of now, six drug candidates have already been identified and licensed to pharmaceutical companies.

learn more

Licenced drug candidates
6
Time period
X years
Acceleration
X,000

Company

  • Artem Cherkasov, PhD

    Co-Founder & CTO

    Artem
    Cherkasov, PhD

    Co-Founder & CTO

    Professor of Medicine at the University of British Columbia and a lead expert in AI-enabled drug discovery.

  • Mads Daugaard, PhD

    Co-Founder & CEO

    Mads
    Daugaard, PhD

    Co-Founder & CEO

    A translational scientist and entrepreneur with expertise in oncology, commercialization, and team building.

Where time, place, and minds align.

Outline: company, founded, approach, founders, partners, collaborators, team. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Nullam dictum felis eu pede mollis pretium. Integer tincidunt. Cras dapibus. Vivamus elementum semper nisi.

learn more

Pipeline

Lorem Ipsum the progress

Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi. Nam eget dui. Etiam rhoncus.

learn more

Target Disease indication Late Discovery Lorem Ipsum Preclinical Phase 1/2
XYZ01 Lorem ipsum dolor sit Phase 1/2 see case
XYZ02 Lorem ipsum dolor sit Preclinical see case
XYZ03 Lorem ipsum dolor sit Preclinical
XYZ04 Lorem ipsum dolor sit Preclinical
XYZ05 Lorem ipsum dolor sit Lorem Ipsum
XYZ06 Lorem ipsum dolor sit Lorem Ipsum

Investor Relations

Aenean vulputate eleifend tellus. Aenean leo ligula

Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi. Nam eget dui. Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem.

learn more

Updates

News

view all

Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor

Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi. Nam eget dui.

learn more

Latest Publications

view all

Artificial intelligence–enabled virtual screening of ultra-large chemical libraries with deep docking

Nature Protocols 17 (3), 672-697, 2022

F. Gentile, JC. Yaacoub, J. Gleave, M. Fernandez, AT. Ton, F. Ban, A. Stern, A. Cherkasov

learn more

The transformational role of GPU computing and deep learning in drug discovery

Nature Machine Intelligence 4 (3), 211-221, 2022

M. Pandey, M. Fernandez, F. Gentile, O. Isayev, A. Tropsha, AC. Stern, A. Cherkasov

learn more